Home-based Cardiovascular Rehabilitation in Young Patients With Congenital Heart Disease: the "Muscle Your Heart" Program
NCT ID: NCT07115589
Last Updated: 2025-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
21 participants
INTERVENTIONAL
2026-01-01
2026-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rehabilitation of Adolescents and Young Adults With Congenital Heart Diseases
NCT03690518
Neuro-cardiac Rehabilitation in Youth With Congenital Heart Disease (QUALINEUROREHAB)
NCT05670132
Cardiac Rehabilitation for Young People
NCT05968521
Cardiac Rehabilitation in Congenital Heart Disease: Effects on Brain and Cognitive Functions
NCT05195788
Start-to-Sport - Home-based Exercise for Adolescents and Adults With Congenital Heart Disease
NCT02240147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, this program has limitations, including the need for a medical care and rehabilitation centre near the patient's home.
This study, evaluating the impact of a 3-month cardiovascular rehabilitation program entirely at home, will improve this program by taking into account its limitations and will apply it to real life, without all the human, financial and material resources of a randomized controlled trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
fully home-based cardiovascular rehabilitation program
3-month cardiovascular rehabilitation program entirely at home, combining adapted physical activity, therapeutic education and psychosocial support
Muscle Your Heart home-based program
2 one-hour sessions of adapted physical activity per week - HIIT and free adapted physical activity - 1 one-hour monthly therapeutic patient education session - A dedicated platform - Adapted physical activity educators - Dedicated education therapeutic nurses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Muscle Your Heart home-based program
2 one-hour sessions of adapted physical activity per week - HIIT and free adapted physical activity - 1 one-hour monthly therapeutic patient education session - A dedicated platform - Adapted physical activity educators - Dedicated education therapeutic nurses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Follow-up for congenital heart disease in the ACC-CHD classification.
* Patient aged 8 to 25 years at the time of inclusion.
* Consent of the adult patient or the parents or legal guardians of the minor patient.
* Social security affiliation (excluding AME).
* VO2max and/or SV1 \< -1.64 z-score for patients aged 8 to 17 years or VO2max \< 80% and/or SV1 \< 55% of theoretical VO2max for patients aged 18 to 25 years
Exclusion Criteria
* Severe hypoxemia: pulse oxygen saturation (SpO2) at rest \< 85%, and/or SpO2 at exercise \< 80%, and/or patient requiring oxygen therapy.
* Pulmonary hypertension as defined by the 2020 ESC guidelines, whatever the aetiology.
* Significant systolic right ventricle (sRV) hypertension (Srv pressure \> 50% of systemic systolic pressure).
* Uncontrolled arrhythmia: symptomatic arrhythmia treated or untreated at rest and/or during exercise, treated arrhythmia with sustained supraventricular or ventricular tachycardia on ECG monitoring or during exercise and/or CPET, occurrence or aggravation of any supraventricular or ventricular arrhythmia during exercise and/or CPET.
* Advanced atrioventricular block (degree 2 or 3), occurrence or aggravation of any conduction disorder during exercise and/or CPET.
* Uncontrolled arterial hypertension at rest (blood pressure at rest during the consultation \> 140/90 mmHg in adults, \> 95th percentile in children).
* Acute or recent myocarditis and pericarditis (\< 3 months).
* Symptomatic aortic or subaortic stenosis (mean gradient \> 50 mmHg).
* Non-corrected coarctation of the aorta (surgical or catheter-based repair) with a clinical systolic gradient \> 20 mmHg.
* Dilatation of the aorta (aortic root \> 40 mm in adults, \> 2 z-score in children) (http://www.parameterz.com/sites/aortic-root) except in the case of repaired CHD with dilatation of the aorta inherent in the malformation and without risk of aortic dissection (tetralogy of Fallot, transposition of the great vessels, pulmonary atresia IVC, common trunk artery).
* Severe obstructive hypertrophic cardiomyopathy.
* Acute systemic disease.
* Recent intracardiac thrombus (\< 3 months), embolism or thrombophlebitis.
* Inability to follow instructions and/or home rehabilitation and/or answer questionnaires, as determined by the investigator.
* Absolute contraindications for CPET: fever, uncontrolled asthma, respiratory failure, acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, uncontrolled heart failure, acute pulmonary embolus or pulmonary infarction, and patients with mental impairment leading to inability to cooperate.
* Inability to undergo the physical intervention: inability to physically exercise, any invasive medical intervention occurring within 6 months preceding the inclusion or scheduled during the 3-month study period (such as cardiac surgery, catheter-based intervention, orthopedic surgery, chemotherapy for cancer, or any other significant medical treatment or intervention, as determined by the investigator).
* For female patients: pregnancy, planning to become pregnant, or breastfeeding woman following questioning of the patient.
* Any other clinical and/or pharmacological treatment that is believed to interfere with the study or the optimal clinical care.
* Patients deprived of their liberty due to ongoing legal procedure, adult patients under guardianship or curatorship, or unable to personally express their consent.
* Patients who have benefited from cardiovascular rehabilitation in the 12 months preceding inclusion.
* Patient participating or wishing to participate in any interventional clinical research (drug trial, medical device, non-drug trial).
8 Years
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pr Pascal AMEDRO, MD,PhD
Role: STUDY_DIRECTOR
CHU de Bordeaux - Hôpital Cardiologique Haut Lévêque
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Bordeaux - Hôpital Cardiologique Haut Lévêque
Pessac, France, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Amedro, P., Gavotto, A., Guillaumont, S., Bertet, H., Vincenti, M., De La Villeon, G., et al. (2018). Cardiopulmonary fitness in children with congenital heart diseases versus healthy children. Heart (British Cardiac Society), 104(12), 1026-1036.
Amedro, P., Dorka, R., Moniotte, S., Guillaumont, S., Fraisse, A., Kreitmann, B., et al. (2015). Quality of Life of Children with Congenital Heart Diseases: A Multicenter Controlled Cross-Sectional Study. Pediatric cardiology, 36(8), 1588-1601.
Amedro, P., Picot, M. C., Moniotte, S., Dorka, R., Bertet, H., Guillaumont, S., et al. (2016). Correlation between cardio-pulmonary exercise test variables and health-related quality of life among children with congenital heart diseases. International
Longmuir, P. E., \& McCrindle, B. W. (2009). Physical activity restrictions for children after the Fontan operation: disagreement between parent, cardiologist, and medical record reports. American heart journal, 157(5), 853-859
Swan, L., \& Hillis, W. S. (2000). Exercise prescription in adults with congenital heart disease: a long way to go. Heart (British Cardiac Society), 83(6), 685-687
Craig, C. L., Marshall, A. L., Sjöström, M., Bauman, A. E., Booth, M. L., Ainsworth, B. E., Pratt, M., et al. (2003). International physical activity questionnaire: 12-country reliability and validity. Medicine and science in sports and exercise, 35(8
Hagströmer, M., Oja, P., \& Sjöström, M. (2006). The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public health nutrition, 9(6), 755-762
Wind, A. E., Takken, T., Helders, P. J., \& Engelbert, R. H. (2010). Is grip strength a predictor for total muscle strength in healthy children, adolescents, and young adults?. European journal of pediatrics, 169(3), 281-287
Castro-Piñero, J., Ortega, F. B., Artero, E. G., Girela-Rejón, M. J., Mora, J., Sjöström, M., \& Ruiz, J. R. (2010). Assessing muscular strength in youth: usefulness of standing long jump as a general index of muscular fitness. Journal of strength and
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A01806-41
Identifier Type: OTHER
Identifier Source: secondary_id
CHUBX 2024/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.